Analysis of patient tumors suggests that multiple MAP3 kinases (MAP3Ks) are critical for growth and metastasis of cancer cells. MAP3Ks selectively control the activation of extracellular signal-regulated kinase 1/2 (ERK1/2), Jun N-terminal kinase (JNK), p38 and ERK5 in response to receptor tyrosine kinases and GTPases. We used MDA-MB-231 cells because of their ability to metastasize from the breast fat pad to distant lymph nodes for an orthotopic xenograft model to screen the function of seven MAP3Ks in controlling tumor growth and metastasis. Stable short hairpin RNA (shRNA) knockdown was used to inhibit the expression of each of the seven MAP3Ks, which were selected for their differential regulation of the MAPK network. The screen identified two MAP3Ks, MEKK2 and MLK3, whose shRNA knockdown caused significant inhibition of both tumor growth and metastasis. Neither MEKK2 nor MLK3 have been previously shown to regulate tumor growth and metastasis in vivo. These results demonstrated that MAP3Ks, which differentially activate JNK, p38 and ERK5, are necessary for xenograft tumor growth and metastasis of MDA-MB-231 tumors. The requirement for MAP3Ks signaling through multiple MAPK pathways explains why several members of the MAPK network are activated in cancer. MEKK2 was required for epidermal growth factor receptor and Her2/Neu activation of ERK5, with ERK5 being required for metastasis. Loss of MLK3 expression increased mitotic infidelity and apoptosis in vitro. Knockdown of MEKK2 and MLK3 resulted in increased apoptosis in orthotopic xenografts relative to control tumors in mice, inhibiting both tumor growth and metastasis; MEKK2 and MLK3 represent untargeted kinases in tumor biology for potential therapeutic development.
Introduction
In mammalian cells, 22 defined MAP3 kinases (MAP3Ks), 11 MAP2Ks and 7 MAPKs comprise a signaling network involving at least 40 protein kinases (Cuevas et al., 2007) . The MAPK network represents approximately 8% of the human kinome and as such it is not surprising that members of the MAPK signaling network are frequently amplified, overexpressed and activated in cancer (Wagner and Nebreda, 2009 ). Elevated expression and/or activation of Jun N-terminal kinase (JNK), p38 and extracellular signal-regulated kinase 5 (ERK5) has been demonstrated in many cancers, including breast, prostate, squamous and hepatocellular carcinoma, and generally correlate with poor survival (Davidson et al., 2006; Hui et al., 2008; McCracken et al., 2008; Sticht et al., 2008; Montero et al., 2009; Zen et al., 2009; Wang et al., 2010) . Thus, despite the prominent role of the Ras-Raf-MEK1/2-ERK1/2 pathway in cancer, patient tumor analysis suggests that other kinases within the MAPK network are critical for growth and metastasis of cancer cells.
Activation of the ERK1/2, JNK, p38 and ERK5 MAPKs is controlled by upstream MAP3Ks that are frequently dysregulated in cancer cells. Activating mutations of B-Raf are found in B7% of all tumors and about 60% of melanomas, resulting in constitutive activation of ERK1/2 (Davies et al., 2002) . In these tumors, activating B-Raf mutations correlate with poor survival, recurrence and resistance to chemotherapy (Samowitz et al., 2005; Sheridan et al., 2008) . The MAP3K Tpl2 has been shown to be amplified and overexpressed in 40% of human breast cancers (Sourvinos et al., 1999) . A predicted activating Tpl2 mutation was also found in a patient with primary basal-like breast cancer and cells containing this Tpl2 mutation were preferentially enriched in a metastasis from the primary tumor (Ding et al., 2010) . The MAP3Ks, MEKK3 and A-Raf, were found recently to be overexpressed in non-small-cell lung cancer (Lee et al., 2010) .
Despite the overwhelming evidence from the analysis of patient tumor samples that the MAPK signaling network is significantly dysregulated in cancer, there is little definitive understanding of the actual function of MAP3K signaling in regulating tumor growth and metastasis. The exception is the MAP3Ks, B-Raf and c-Raf, that enhance cell proliferation through ERK1/2 signaling (Davies et al., 2002) . Most MAP3Ks regulate at least two different MAPKs such as JNK and p38 (for example, MLK3) or ERK5 and JNK (for example, MEKK2) (Kesavan et al., 2004; Brancho et al., 2005; Cuevas et al., 2007) . Thus, the MAPK signaling network should be viewed not simply as multiple independent pathways, but as a cooperative network involving many MAP3Ks that dynamically integrate different cellular stimuli to coordinately activate downstream MAPKs.
In this study, we used the triple-negative MDA-MB-231 claudin-low breast cancer line to assess seven MAP3Ks for their role in tumor growth and metastasis through selective short hairpin RNA (shRNA) knockdown using orthotopic breast fat pad xenografts (Prat et al., 2010) . The orthotopic xenograft screen was carried out with MDA-MB-231 cells because they are the only line we tested that gave significant metastasis to distant lymph nodes; this was not true for other lines tested, including SUM149, SUM159, Hs578T and BT474 cells. Our aim was to identify MAP3Ks whose loss of expression could inhibit metastasis in addition to tumor growth. We analyzed seven MAP3Ks expressed in MDA-MB-231 cells representing a cross-section of the MAP3Ks that differentially regulate ERK1/2, JNK, p38 and ERK5. Except for B-Raf, MAP3Ks chosen for the study represent 'untargeted kinases' in that they are generally poorly characterized in disease models including cancer. The findings identified two MAP3Ks previously untargeted in cancer that were required for tumor growth and metastasis of MDA-MB-231 cells.
Results

MAP3Ks control tumor growth and metastasis
We set out to test the role of specific MAP3Ks in tumor growth and metastasis using MDA-MB-231 cells. To start, we used small interfering RNA (siRNA) knockdown of kinases in the MAPK network and measured cell proliferation and possible synthetic lethal phenotypes in the presence of MEK1/2, JNK or p38 inhibitors ( Supplementary Figures S1A-C) . The screen showed that growth of MDA-MB-231 cells in culture was dependent on the expression of ERK2 (MAPK1) and partially on the upstream MAP3K B-Raf. Knockdown of other kinases in the network did not significantly inhibit proliferation in the presence or absence of inhibitors, even though JNK small-molecule inhibitor strongly inhibited growth of the cells similar to that seen with MEK1/2 inhibitor (Supplementary Figure S1D) . It was decided that such in vitro assays were inadequate and a more functional assay was needed to test the role of MAP3Ks, for example, those activating JNK or ERK5, for control of MDA-MB-231 tumorigenesis. We therefore chose to use stable shRNA knockdown in MDA-MB-231 cells and orthotopic breast fat pad xenografts to test the function of specific MAP3Ks. Seven MAP3Ks expressed in MDA-MB-231 cells that differentially regulate ERK1/2, JNK, p38 and ERK5 were selected for stable shRNA knockdown for analysis in orthotopic xenografts. Figure 1a shows the seven MAP3Ks and their regulation of downstream MAPKs chosen for shRNA knockdown. The MAP3Ks selected for shRNA knockdown signal through ERK1/2 (B-Raf and Tpl2), ERK1/ 2 and JNK (MEKK1), JNK and p38 (TAK1, MLK3), JNK and ERK5 (MEKK2) or p38 and ERK5 (MEKK3). In general, two or more shRNAs were used for creating independent knockdown lines for each MAP3K. Ultrasound and bioluminescent imaging (BLI) enabled longitudinal tracking of tumor growth and metastasis of cells having shRNA knockdown of MAP3Ks (Figure 1b ). Knockdown of each kinase was assessed by either western blotting or real-time polymerase chain reaction in the cells before implantation in the mammary fat pad and in metastases after the animal was killed at 6-8 weeks post-tumor initiation (Supplementary Figures S2A-L).
MEKK1.
We have previously shown that RNA interference-mediated loss of MEKK1 expression in MDA-MB-231 cells resulted in significant inhibition of both cell migration and invasion through Matrigel (Cuevas et al., 2006) . Mammary fat pad orthotopic xenografts of MDA-MB-231 cells having knockdown of MEKK1 formed tumors similar to wild-type cells, but failed to metastasize to lymph nodes during a 12-week longitudinal study (Figures 1c and d) . In contrast, four mice having wild-type MDA-MB-231 cells injected into mammary fat pads each developed metastases. The results with MDA-MB-231 orthotopic xenografts were similar to our studies with the MMTV-PyMT mouse breast cancer model, where mammary tumors developed metastases and targeted deletion of MEKK1 significantly delayed breast cancer metastasis, while tumor growth was unchanged (Cuevas et al., 2006) . The significant delay of metastasis was due in part to a loss of urokinase type-1 plasminogen activator expression, which is also seen in MDA-MB-231 cells having RNA interference knockdown of MEKK1 (Cuevas et al., 2006) . Similar in vivo phenotypes with shRNA knockdown of MEKK1 in MDA-MB-231 cells implanted in the mammary fat pad and targeted deletion of MEKK1 in the MMTV-PyMT mouse validated MDA-MB-231 orthotopic xenografts as a model to assess MAP3K signaling in controlling metastasis. We therefore used this orthotopic xenograft assay to screen functional consequences of shRNA knockdown of six additional MAP3Ks in MDA-MB-231 cells. The aim was to discover understudied MAP3Ks required for tumor growth and metastasis.
B-Raf and Tpl2. B-Raf and Tpl2 each regulate ERK1/ 2 activity. Similar to the siRNA screen (Supplementary Figure S1 ), stable shRNA knockdown of B-Raf resulted in decreased MDA-MB-231 cell growth and ERK1/2 activity in cultured cells (Figures 2a-d) . In knockdown xenografts, with 90% loss of B-Raf protein expression (Supplementary Figure S2A) , tumors were still able to implant, but were significantly smaller in size, consistent with decreased tumor cell proliferation (Figures 2e and  g) . Tumors having B-Raf knockdown formed metastases at what appeared to be a somewhat lower frequency than control cells (Figures 2f and h) . However, with a total of 13 and 12 mice with control and B-Raf knockdown tumors, respectively, the difference in the number of metastases was not statistically significant (P pooled ¼ 0.23). At 7-8 weeks post-tumor implant, the bioluminescent photon flux measurements of metastases from B-Raf knockdown tumors was less Ultrasound was used to assess tumor volume and BLI was used to identify metastases. Ultrasound and BLI measurements were generally started at week 3 or 4 post-injection and performed weekly until the animal was killed. (c, d) As proof of concept, MEKK1 was shown to inhibit metastasis, but not tumor growth. MEKK1 was previously shown in the PyMT mammary adenocarcinoma model to suppress metastasis, but not tumor mass (Cuevas et al., 2006) . (c) Tumor mass (mean ± s.e.m.) of control (n ¼ 4) and MEKK1 shRNA (n ¼ 3) MDA-MB-231 cells measured at 12 weeks post-injection at the time of being killed. (d) BLI for detection of metastases from tumors formed from control cells or MEKK1 shRNA cells measured at 12 weeks post-injection at the time of being killed. Supplementary  Table S1 ).
Tpl2 knockdown, like B-Raf, also had an inhibitory effect on xenograft tumor growth ( Figures 3a and b ), even though Tpl2 knockdown did not inhibit cell growth in vitro (Supplementary Figure S1 ). In all, 6 of 15 mice with Tpl2 knockdown tumors formed metastases compared to five of eight mice with tumors from control cells (Figures 3a-c), which was not statistically significantly different for the two conditions (P pooled ¼ 0.40). Bioluminescent photon flux measurements of metastases from Tpl2 knockdown tumors were less compared with control tumors, similar to that observed with B-Raf ( Supplementary Table S1 ). Thus, both B-Raf and Tpl2 knockdown inhibited tumor cell growth in vivo, consistent with both MAP3Ks playing a critical role in controlling proliferation.
MEKK3 and TAK1. MEKK3 binds the scaffold protein p62/sequestosome 1 and localizes in cytosolic aggregates or speckles for the control of nuclear factor-kB (Nakamura et al., 2010) . MEKK3 also regulates JNK and ERK5 independent of p62/sequestosome 1. Similar to B-Raf and Tpl2, knockdown of MEKK3 inhibited tumor presented as mean ± s.e.m., n ¼ 6 (control and B-Raf shRNA 1) and n ¼ 7 (control for B-Raf shRNA 2) or n ¼ 6 (B-raf shRNA 2) *Po0.05, **Po0.01 by unpaired t-test. (h) Number of metastasis positive mice at the time of being killed (day 55 post-injection for control, shRNA1 and 2 mice). P-values for pooled control mice versus pooled B-Raf shRNA mice were calculated by Fisher's exact test. Note: the control cohort for B-Raf shRNA 1 and TAK1 shRNA 1 are derived from the same experiment as they were carried out at the same time.
growth, but did not change the frequency of metastasis (Figures 3d-f ).
Knockdown of TAK1, which also regulates JNK and p38, had no effect on tumor growth or the frequency of metastases (Figures 3g-i). Only one shRNA is shown for TAK1 because other shRNAs did not sustain knockdown over a 7-week longitudinal study in mice (Supplementary Figure S2 and data not shown). The fact that metastases retained TAK1 knockdown with shRNA1 indicated that TAK1 is not essential for metastases.
MEKK2. MEKK2 regulates ERK5 activation in response to growth factor receptor tyrosine kinases (Sun et al., 2003; Kesavan et al., 2004) . MEKK2 immunoprecipitation identified epidermal growth factor receptor (EGFR) as a co-immunoprecipitating protein (data not shown), indicating that MEKK2 and EGFR are in a signaling complex in cells. We found that MEKK2 knockdown inhibits activation of ERK5 in response to EGF in MDA-MB-231 cells (Figure 4a ), as well as SUM159 and Hs578T cells ( Supplementary  Figures S3A and B) . In contrast to ERK5 signaling, ERK1/2 and JNK1 activation was unchanged. Previous studies suggested that MEKK2 activates ERK5 in a Srcdependent manner (Sun et al., 2003) , so we tested if Src was required for EGF-stimulated ERK5 activation using the Src inhibitors PP2 and Dasatinib, the inactive inhibitor PP3 and the highly selective EGFR/Her2 inhibitor Lapatinib. EGFR phosphorylation and ERK5 activation was dependent on EGFR kinase activity and MEKK2-dependent ERK5 activation is enhanced, but not dependent on Src (Figure 4b) .
Overexpression of the EGFR family member Her2/ Neu in BT474 cells constitutively activates ERK5 (Montero et al., 2009) . MEKK2 knockdown blocked constitutive activation of ERK5 in BT474 cells (Figure 4c ). Although ERK5 was predominantly in the activated, gel-shifted state in control cells, ERK5 was in the inactive, dephosphorylated form in MEKK2 shRNA knockdown cells. This was accompanied by an increase in JNK phosphorylation, whereas ERK1/2 activation remained unchanged.
shRNA knockdown of MEKK2 strongly inhibited both tumor growth and metastasis (Figures 4d-g) .
Knockdown of MEKK2 showed diminished tumor growth, resulting in tumors that were B10-33% the size of control tumors. Metastasis was detected in only one of 12 mice from MEKK2 shRNA knockdown tumors versus 7 of 13 mice injected with control cells (Figures 4e and g) , giving a highly significant inhibition of measurable metastases (P pooled ¼ 0.0155). The small tumor size allowed mice harboring MEKK2 knockdown tumors to be maintained in a healthy state for longer times to monitor metastasis. Metastasis was delayed >5 weeks (7 weeks in controls versus 412 weeks in MEKK2 shRNA tumors) with MEKK2 shRNA tumors, with the metastases retaining knockdown of MEKK2 during the duration of the experiment (Supplementary Figure S2K ). These results were confirmed in a second set of animals ( Supplementary Figures S3C   Figure 4 MEKK2 mediates activation of ERK5 by EGFR and Her2 and is required for tumor growth and metastasis. (a) MEKK2 knockdown inhibits ERK5 activation in response to EGF. Cells were stimulated with 10 ng/ml EGF for the indicated times and blotted for ERK5, phospho-ERK1/2 and phospho-JNK. For ERK5 blots, long exposures were performed to identify the super-shifted phosphorylated form of ERK5 (arrows), while shorter exposures were performed to demonstrate equal loading of samples. (b) Requirement of EGFR and Src for ERK5 activation in MDA-MB-231 cells. Cells were serum-starved and treated with dimethyl sulfoxide control, PP2, PP3, Dasatinib or Lapatinib for 15 min before stimulation with 10 ng/ml EGF for 15 min. Cells were lysed and blotted for total ERK5, Src family phospho-Y416, EGFR phospho-Y1068 or actin as a loading control. (c) Lysates from control and MEKK2 shRNA expressing BT474 cells were blotted for ERK5, MEKK2, phospho-ERK1/2, phospho-JNK or tubulin as a loading control. MEKK2 knockdown was accompanied by a marked loss of the super-shifted phospho-ERK5. (d) Ultrasound images of control and MEKK2 knockdown tumors 55 days post-injection. (e) BLI detection of metastases in mice having control and MEKK2 knockdown tumors. (f) Quantitation of tumor volume in control and MEKK2 knockdown determined by ultrasound imaging (tumor area is denoted with yellow line). Each data point, data are presented as mean ± s.e.m. for n ¼ 7 and 6 (control and MEKK2 shRNA 1) or n ¼ 6 (control and MEKK2 shRNA 2). *Po0.05, **Po0.002 by unpaired t-test. (g) Number of metastasis-positive mice at the time of being killed (51 days post-injection for control and shRNA 1 or 55 days post-injection for control and shRNA 2). P-values for pooled control mice versus pooled MEKK2 shRNA mice were calculated by Fisher's exact test. (h) MEKK2 knockdown inhibits tumor growth of BT474 cells. BLI of flank tumors from mice injected with control or MEKK2 knockdown BT474 cells at 45 days postinjection of cells. (i) Quantitation of tumor photon flux from control and MEKK2 shRNA BT474 tumors. Bars represent mean ± s.e.m. for each cell type, n ¼ 12 (control) and n ¼ 10 (MEKK2 shRNA 1); *Po0.05 versus control. and D), with the difference in the number of metastases being highly significant between control and MEKK2 knockdown tumors (P pooled ¼ 0.0094). Increased apoptosis assayed by TUNEL (terminal deoxynucleotidyl transferase dUTP nick-end labeling) was observed with the loss of MEKK2 expression in xenografts versus size-matched control tumors (Supplementary Figure  S3E) , although growth of MEKK2 knockdown cells in culture was the same as wild-type cells (Supplementary Figure S3F ).
Tumor growth of MEKK2 shRNA knockdown in BT474 cell xenografts was also inhibited (Figure 4h ). BLI analysis showed a 12-fold decrease in photon flux in MEKK2 shRNA tumors relative to control (Figure 4i ). Thus, MEKK2 is critical for EGFR-and Her2/Neu tyrosine kinase-dependent ERK5 activation, tumor growth of both MDA-MB-231 and BT474 cells, and metastasis of MDA-MB-231 cells.
ERK5
knockdown inhibits metastasis. Because MEKK2 is required for EGFR activation of ERK5, we next assessed whether knockdown of ERK5 in MDA-MB-231 cells would show similar tumor growth and metastasis phenotypes as with MEKK2 knockdown. Two different shRNAs were used to inhibit ERK5 expression ( Figure 5a ). ERK5 knockdown resulted in a decrease in metastasis without a significant effect on tumor growth (Figures 5b and c) . Only one of 10 animals injected with ERK5 shRNA knockdown cells had lymph node metastasis. Thus, MEKK2 regulation of ERK5 is only one arm of MEKK2 signaling controlling tumor growth and metastasis.
Inhibition of tissue factor-associated microparticle release in MEKK2 knockdown cells. Growth of MEKK2 knockdown cells was normal in vitro, indicating the MEKK2-MEK5-ERK5 pathway is not required for proliferation in culture (Supplementary Figure S3F ). This contrasts with the inhibition of xenograft tumor growth and metastasis, so we screened for secreted factors, including proteases and cytokines that could affect xenograft tumor properties ( Supplementary Table  S2 ). We screened for 88 secreted analytes (http://www. rulesbasedmedicine.com/products-services/humanmapservices/humanmap/) using control, MEKK2 and MLK3 shRNA knockdown MDA-MB-231 cells. Of the 88 analytes tested, only tissue factor (TF) was significantly reduced in the culture supernatants from the MEKK2 knockdown cells compared with wild-type cells (Figure 5d) . A reduced level of TF in the culture supernatant was confirmed using a TF enzyme-linked immunosorbent assay (Figure 5e ). Importantly, levels of cellular TF activity were similar in MEKK2 shRNA cells and control cells (Figure 5f ). TF is a transmembrane receptor that is released from the plasma membrane of tumors cells in the form of microparticles (MPs), the so-called TF þ MPs that are constitutively released from tumor cells (Kasthuri et al., 2009; Rak, 2010) . We showed that the released TF was in the form of MPs by isolating MPs from the culture supernatant and measuring the level of TF activity (Khorana et al., 2008) . We found a significant reduction on TF þ MPs in the culture supernatant from MEKK2 shRNA cells compared with controls (Figure 5g ). Diminished release of TF could also be detected by western blotting of supernatants from MDA-MB-231 cells having either stable shRNA knockdown or transient knockdown of MEKK2 with multiple siRNAs (Figures 5h and i) , demonstrating the on-target effect of MEKK2 knockdown on the release of TF þ MPs from MDA-MB-231 cells. Interestingly, we could not demonstrate that knockdown of ERK5 or inhibition of JNK blocked TF þ MP release from MDA-MB-231 cells (data not shown), suggesting that MEKK2 is part of a signaling complex controlling MP formation and/or release independent of ERK5 or JNK signaling. There was no difference in released TF in the culture supernatants from MLK3 knockdown MDA-MB-231 cells (data not shown). Previous studies have shown that activated Ras and EGFR signaling enhance MP release that contributes to coagulopathy and tumor angiogenesis (Yu et al., 2005; Al-Nedawi et al., 2008; Kasthuri et al., 2009; Rak, 2010) . Thus, MEKK2 is an important member of an EGFR signaling complex controlling cancer cell TF þ MP release that is critical for tumor growth and metastasis.
MLK3. MLK3 expression is required for p38 activation in response to tumor growth factor-b and for JNK activation in response to fatty acids (Figures 6a and b ) (Kim et al., 2004; Jaeschke and Davis, 2007) . Stable MLK3 knockdown by shRNA decreased in vitro proliferation of MDA-MB-231, SUM159 and Hs578T cells (Figure 6c and Supplementary Figures S4A and B ). This growth inhibition was greater than that observed in the transient siRNA screen over a 4-day period.
There was an increase in apoptosis in MLK3 knockdown cells as determined by the percentage of cells with sub-G 0 /G 1 DNA content (Figures 6d and e ). TUNEL staining showed increased fragmented DNA in MLK3 knockdown cells, confirming that loss of MLK3 resulted in increased apoptosis (Figure 6f ). MLK3 has been implicated in controlling microtubule organization with the inhibition of MLK3, resulting in aberrant spindle pole formation in HeLa cells that can result in chromosomal instability (Fodde et al., 2001; Cha et al., 2006) . We found an increase in multinucleated and micronucleated cells with MLK3 knockdown, consistent with MLK3 deficiency inducing mitotic infidelity in MDA-MB-231 cells (Figures 6g and h) .
shRNA knockdown of MLK3 had a pronounced inhibition of tumor growth in mice (Figures 6i and k) . The tumors remained very small over time with little evidence of continued tumor expansion. TUNEL assay for apoptotic cells in size-matched MLK3 knockdown and control xenografts showed a significant increase in apoptosis in the tumors having loss of MLK3 expression ( Supplementary Figure S4F) , consistent with the increased apoptosis observed in culture. Loss of MLK3 expression also strongly inhibited tumor metastasis (Figures 6j and l) . Because of the dramatic xenograft phenotype, we tested a third shRNA targeting MLK3, which demonstrated a similarly pronounced inhibition of tumor growth and metastasis (Figure 6m and Supplementary Figure S4C) . Only a single mouse out of 32 mice injected with MLK3 shRNA cell lines developed a lymph node metastasis, while 12 of 22 mice were positive for metastasis from control MDA-MB-231 cell tumors. Similar results were observed when the MLK3 shRNA cell lines were injected into the flank rather than the fat pad ( Supplementary Figures S4D and E) , indicating that MLK3 knockdown strongly inhibited MDA-MB-231 cell tumor growth independent of the tumor microenvironment. Thus, loss of MLK3 expression markedly inhibited both tumor growth and metastasis, giving the most dramatic phenotype of the seven MAP3K knockdowns tested in the orthotopic xenograft assay. Figure 6 Knockdown of MLK3 induces apoptosis and inhibits tumorigenesis. (a) MLK3 knockdown inhibits JNK activation by free fatty acid. Control, MLK3 shRNA 1 and MLK3 shRNA 2 cell lines were treated with either 0.5% fatty acid free bovine serum albumin or 0.5 mM palmitate in 0.5% fatty acid free bovine serum albumin for 18 h and lysates analyzed for phospho-JNK. (b) MLK3 knockdown inhibits tumor growth factor-b-stimulated p38 activation. Control and MLK3 shRNA 1 or control and MLK3 shRNA 2 cell lines were serum-starved and treated with 5 ng/ml tumor growth factor-b for different times and analyzed for phospho-p38 or total ERK5 as a loading control. (c) Growth of control and MLK3 shRNA MDA-MB-231 cell lines over 4 days measured using the Cell TiterGlo viability assay. Individual measurements were normalized to day 0 signal. Each data point is the mean ± s.e.m. of quadruplicate samples. Each data point is mean±s.e.m., n ¼ 8 (control and MLK3 shRNA 1) or n ¼ 7 and 8 (control and MLK3 shRNA 2); *Po0.01 by unpaired t-test. (l, m) Number of metastasis-positive mice at the time of being killed at 74 days (control and MLK3 shRNA 1), 73 days (control and MLK3 shRNA 2) or 51 days (control, MLK3 shRNA 1 and MLK3 shRNA 3). P-values for pooled control mice versus pooled MLK3 shRNA mice were calculated by Fisher's exact test.
Discussion
The orthotopic xenograft screen of MDA-MB-231 cells proved insightful and led to the discovery of two kinases not previously defined to regulate tumor growth and metastasis. Six of the seven MAP3Ks tested had some regulatory function in controlling tumor growth and/or metastasis, showing that a collective group of MAP3Ks contribute to driving the tumor phenotype. Evident in our data are the separation of tumor size and the ability to metastasize (that is, B-Raf, Tpl2, MEKK3). This is consistent with previous observations that small tumors may readily metastasize and large tumors may not metastasize (Sidebottom and Clark, 1983; Husemann et al., 2008; Wo et al., 2011) . Our findings uniquely defined MEKK2 and MLK3 as regulating both tumor growth and metastasis. The findings explain why multiple members of the MAPK network are overexpressed and/or activated in many cancers, so as to coordinately activate ERK1/2, JNK, p38 and ERK5. Loss of individual MAP3Ks by shRNA knockdown can significantly compromise the network such that tumor growth and/or metastasis are inhibited. If one uses stringent criteria that both tumor growth and metastasis must be inhibited, only MEKK2 and MLK3 of the MAP3Ks tested would be considered potential new therapeutic targets. Targeting MLK3 inhibition warrants particular focus because its loss of expression induced apoptosis while strongly inhibiting tumor growth and metastasis, both important criteria for regression of the primary tumor and prevention of metastatic spread.
The involvement of MEKK2 in cancer is not limited to breast cancer; a recent study has linked MEKK2 to prostate cancer. MEKK2 was expressed at 4.4-fold higher level in prostate cancer tissue versus benign tissue and even higher levels of MEKK2 expression were observed in LNCaP, Du145 and PC3 prostate cell lines (Cazares et al., 2009) . Overexpression of ERK5 and MEK5 has also been demonstrated to be important prognostic factors in prostate cancer (Mehta et al., 2003; McCracken et al., 2008) . Although inhibitors of ERK5 signaling have been characterized to inhibit the growth of specific tumors (Yang et al., 2010) , our findings suggest that inhibition of MEKK2 would have greater clinical benefit than inhibiting ERK5 alone because of the diverse biological role of MEKK2 in the control of ERK5, JNK and TF þ MP release (Tatake et al., 2008; Yang et al., 2010) . In MDA-MB-231 cells, ERK5 does not appear to regulate proliferation, but is involved in controlling metastasis, consistent with the analysis of cancer patient data and outcome (Mehta et al., 2003; Montero et al., 2009) .
Although MLK3 has previously been characterized as proapoptotic in neurons (Mishra et al., 2007) , we find that MLK3 is antiapoptotic in tumor cells. Inducible expression of active MLK3 in MCF10A cells grown in Three-Dimensional Matrigel enhanced migration and inhibited apoptosis , consistent with the inhibition of growth and increased apoptosis in MDA-MB-231 cells having shRNA-mediated MLK3 knockdown. MLK3-dependent proliferation also has been demonstrated in K-Ras mutant pancreatic cancer cell lines using siRNA knockdown of MLK3 or MLK3 small-molecule inhibitors (Chandana et al., 2010) . Mitotic infidelity and increased apoptosis induced by loss of MLK3 expression previously was also shown in vitro with a small-molecule MLK3 inhibitor with cell lines having activated Ras (Cha et al., 2006) . Thus, MLK3 inhibition might serve as a therapeutic target worth investigating for Ras mutant tumors, which are difficult to treat and generally lack molecularly targeted therapies.
MEKK2 and MLK3 are kinases within the untargeted cancer kinome (Fedorov et al., 2010) . Knockdown of MEKK2 and MLK3 inhibited tumor growth to similar or greater extents as knockdown of B-Raf or Tpl-2, but also inhibited metastasis more significantly than B-Raf. Our study predicts that inhibiting MEKK2 and/or MLK3 alone or in combination with B-Raf or MEK1/2 inhibition could have significant benefit in activated Ras-or B-Raf-driven tumors. Previous studies have demonstrated that MLK3 and MEKK2 knockout mice are viable and grossly normal (Guo et al., 2002; Brancho et al., 2005) . Also, small-molecule MLK3 inhibitors were well tolerated in trials for protection against neurodegeneration (Waldmeier et al., 2006) , suggesting that inhibitors for both MEKK2 and MLK3 would likely be well tolerated. Our results show that although labor-intensive, orthotopic xenografts using shRNA knockdown of specific kinases, such as MEKK2 and MLK3, can be an effective method to define the function of untargeted and understudied kinases in cancer.
Materials and methods
Reagents and cell culture Tumor growth factor-b1 and EGF were from Peprotech (Rocky Hill, NJ, USA). U0126, SP600125, SB203580, Dasatinib and Lapatinib were from LC Labs (Woburn, MA, USA). Cell culture reagents were from Invitrogen (Carlsbad, CA, USA). All other reagents were from Sigma (St Louis, MO, USA). For BLI, cells were infected with luciferase-expressing retroviruses and selected on G418. MDA-MB-231 and Hs578t cells were maintained in Dulbecco's modified Eagle's medium/ 10% fetal bovine serum with 1% penicillin/streptomycin. SUM159 cells were maintained in F12 media supplemented with 5% fetal bovine serum, 5 mg/ml human recombinant insulin (Gibco, Invitrogen, Carlsbad, CA, USA), 1 mg/ml hydrocortisone (Sigma) and 1% penicillin/streptomycin. BT474 cells were maintained in Dulbecco's modified Eagle's medium:F12 (1:1) containing 10% fetal bovine serum and 1% penicillin/streptomycin. Cell lines used in this study were authenticated using short tandem repeat profiling.
Knockdown of MAP3Ks in cell lines
Open Biosystems TRCN shRNAs were co-transfected into HEK293 cells with pMD2.G and psPAX2 (Addgene plasmid 12259 and 12260; Trono lab, É cole Polytechnique Fe´de´rale de Lausanne, Lausanne, Switzerland) to produce lentiviral shRNA particles. Lentiviruses containing shRNAs were infected into target cells and were selected with 2 mg/ml puromycin (Clontech, Mountain View, CA, USA). TRCN clone numbers are indicated in Supplementary Figure S2 . For ERK5, TRCN0000001356 and TRCN0000010262 were used to knockdown ERK5.
Tumor xenografts
Mouse experiments were performed in accordance with the UNC Institutional Care and Use Committee and NIH guidelines. Tumor xenografts were established by injecting either 2 Â 10 6 MDA-MB-231 cells or 4 Â 10 6 BT474 cells in a 50:50 mix of SFM:Matrigel into the inguinal fat pad or flank of 8-week-old SCID mice. For BT474 cells, estrogen pellets were used as in Sartorius et al. (2003) . In general, eight mice were used for control and each shRNA knockout line per experiment.
Tumor and metastasis measurements Tumor size was measured by calipers or ultrasound imaging using a Vevo 770 (Visualsonics, Toronto, Ontario, Canada). Tumor volume was calculated using the equation volume ¼ length Â (width 2 /2). Metastasis was measured by injecting mice with 100 ml of luciferin (50 mg/ml; Gold Biotechnology, St Louis, MO, USA) and imaging mice using a Xenogen IVIS 100 (Caliper Lifesciences, Hopkinton, MA, USA). Images of metastases from control and shRNA cell lines were captured under identical imaging conditions at identical times after luciferin injection. Statistical significance of metastases was calculated by Fisher's exact test using Prism (GraphPad Software, La Jolla, CA, USA). Bioluminescent photon flux was measured in tumors and metastases using the Living Image software (Caliper Lifesciences).
Cell viability assays
For each shRNA condition, 1 Â 10 3 MDA-MB-231 cells, 0.5 Â 10 3 SUM159 cells or 2 Â 10 3 Hs578t cells were plated in quadruplicate in 96-well plates. Drugs were added 18 h after plating. On each day, one plate was assayed using CellTiter-Glo reagent (Promega) according to the manufacturer's protocol. Luminescence was measured on a Pherastar microplate reader (BMG Labtech, Cary, NC, USA) and normalized to day 0 values.
Real-time polymerase chain reaction of RNA levels Total cell line RNA was extracted with the RNeasy kit (Qiagen, Valencia, CA, USA). Total RNA (3 mg) was reverse transcribed using the High Capacity cDNA Reverse Transcription kit (Applied Biosystems, Life Technologies, Carlsbad, CA, USA).
Real-time polymerase chain reaction was performed with Taqman gene expression assays (Applied Biosystems) on an Applied Biosystems 7500 Fast Real-Time Polymerase Chain Reaction System by three-step denaturing, annealing and elongation process. Results for all targets were normalized to human b-actin message. siRNA screening of MAPK genes, measurement of TF antigen and activity, western blotting, propidium iodide staining and immunofluorescence can be seen Supplementary Methods.
